Literature DB >> 30396481

Flavonoids as adjuvant in psoralen based photochemotherapy in the management of vitiligo/leucoderma.

U V Shivasaraun1, Raman Sureshkumar2, Chenmala Karthika1, Nethravathi Puttappa1.   

Abstract

Vitiligo is a disorder characterized by the decrease in melanin pigment of skin. This depigmenting disorder has prevalence among worldwide, irrespective of age and sex. There is an existence of different treatment modalities for the management of vitiligo. But irrespective of treatment methods, the main drawback in the management of vitiligo is the occurrence of side effects during the implication of treatment. Among the treatment modalities, photochemotherapy seems to be the better choice of treatment for vitiligo. Photochemotherapy involves the usage of UV rays for photoactivation of the drug to cause photosensitization of skin which in turn leads to repigmentation. The main aim of the study is to develop novel combination strategy of lipid based nanoemulsion gel for the treatment of leucoderma using trimethylpsoralen and flavonoid. We assume that if this hypothesis of combination therapy proves successful it can be used as an additional novel treatment strategy in the management of vitiligo.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30396481     DOI: 10.1016/j.mehy.2018.09.011

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  Development of Gel-in-Oil Emulsions for Khellin Topical Delivery.

Authors:  Joana Pereira; Rita Gonçalves; Margarida Barreto; Clarisse Dias; Fátima Carvalho; António J Almeida; Helena Margarida Ribeiro; Joana Marto
Journal:  Pharmaceutics       Date:  2020-04-26       Impact factor: 6.321

2.  Current evidence to support the therapeutic potential of flavonoids in oxidative stress-related dermatoses.

Authors:  Dehai Xian; Menglu Guo; Jixiang Xu; Yang Yang; Yangmeng Zhao; Jianqiao Zhong
Journal:  Redox Rep       Date:  2021-12       Impact factor: 4.412

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.